Latest market price
10.19
-0.52-4.84%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.10 | Insider Own | 11.04% | Shs Outstand | 182.32M | Perf Week | 5.00% |
| Market Cap | 1.95B | Forward P/E | 31.11 | EPS next Y | 0.34 | Insider Trans | -1.84% | Shs Float | 173.10M | Perf Month | 15.78% |
| Enterprise Value | 2.11B | PEG | — | EPS next Q | 0.03 | Short Float | 4.64% | Perf Quarter | 31.73% | ||
| Income | -17.00M | P/S | 5.83 | EPS this Y | — | Short Ratio | 3.59 | Perf Half Y | 70.54% | ||
| Sales | 335.00M | P/B | — | EPS next Y | — | ROA | -4.17% | Short Interest | 8.03M | Perf YTD | 36.43% |
| Book/sh | -0.05 | P/C | 16.00 | EPS next 5Y | — | ROE | — | 52W High | 11.42 -10.76% | Perf Year | 11.33% |
| Cash/sh | 0.67 | P/FCF | 34.87 | EPS past 3/5Y | — | ROIC | 12.51% | 52W Low | 5.25 94.13% | Perf 3Y | 519.08% |
| Dividend Est. | — | EV/EBITDA | 132.17 | Sales past 3/5Y | 38.46% 70.95% | Gross Margin | 83.34% | Volatility | 3.14% 4.65% | Perf 5Y | 488.46% |
| Dividend TTM | — | EV/Sales | 6.31 | EPS Y/Y TTM | — | Oper. Margin | 10.91% | ATR (14) | 0.48 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 1.02 | Sales Y/Y TTM | 36.18% | Profit Margin | -5.12% | RSI (14) | 60.02 | Recom | 2.09 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.45 | EPS Q/Q | — | SMA20 | 2.74% | Beta | 0.83 | Target Price | 15.00 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | 27.78% | SMA50 | 15.05% | Rel Volume | 0.66 | Prev Close | 10.71 |
| Employees | 435 | LT Debt/Eq | — | Earnings | Nov 05 | SMA200 | 42.81% | Avg Volume | 2.35M | Price | 10.19 |
| IPO Date | Jun 21, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1582.34% 0.98% | Net Debt/EBITDA | 10.13 | Volume | 1,544,849 | Change | -4.84% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-06-26 | Reiterated | Barclays | Overweight | $12 → $14 |
| Sep-10-26 | Reiterated | Leerink Partners | Outperform | $16 |
| Aug-20-26 | Reiterated | Barclays | Overweight | $9.00 → $12 |
| Dec-08-25 | Initiated | Barclays | Overweight | $9.00 |
| Oct-29-25 | Reiterated | Oppenheimer | Outperform | $5.00 → $18 |
| Mar-07-25 | Reiterated | Piper Sandler | Neutral | $3.00 → $4.00 |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Nov-11-24 | Reiterated | HC Wainwright & Co. | Buy | $6.60 |
| Oct-23-24 | Reiterated | Oppenheimer | $5.00 | |
| May-10-24 | Reiterated | Piper Sandler | Overweight | $3.00 |
Latest News· Times ET
Oct-26-26
Oct-23-26
Oct-23-2608:13PM
Oct-22-26
Oct-22-2609:00AM
Oct-17-26
Oct-17-2603:29AM
Oct-15-26
Oct-15-2608:00AM
Oct-10-26
Oct-10-2612:19PM
Oct-08-26
Oct-08-2603:15PM
Oct-06-26
Oct-04-26
Oct-04-2602:14PM
Oct-02-26
Oct-02-2605:00PM
Sep-30-26
Sep-30-2606:21AM
Sep-29-26
01:44PM
Sep-23-26
Sep-23-2606:02AM
Sep-21-26
Sep-21-2602:15AM
Company
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 335 | 292 | 203 | 164 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 56 | 53 | 37 | 29 | — | — | — | — | — | |
| Gross Profit | 280 | 238 | 166 | 135 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 208 | 182 | 163 | 146 | — | — | — | — | — | |
| Research and Development | 35 | 31 | 26 | 22 | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 11 | 11 | — | — | — | — | — | |
| Operating Income | 37 | 25 | -34 | -44 | — | — | — | — | — | |
| Interest Expense | 28 | 29 | 33 | 27 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -26 | 5 | 10 | 7 | — | — | — | — | — | |
| Net Income Before Taxes | -17 | 1 | -57 | -64 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | -2 | -1 | — | — | — | — | — | |
| Consolidated Net Income | -17 | 1 | -55 | -62 | — | — | — | — | — | |
| Net Income From Continuing Operations | -17 | 1 | -55 | -62 | — | — | — | — | — | |
| Net Income | -17 | 1 | -55 | -62 | — | — | — | — | — | |
| EPS (Recurring) | -0.10 | 0.00 | -0.37 | -0.45 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.10 | 0.00 | -0.37 | -0.45 | — | — | — | — | — | |
| EPS (Diluted) | -0.10 | 0.00 | -0.37 | -0.45 | — | — | — | — | — | |
| EBITDA | 16 | 13 | -14 | -24 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 2,453.12 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.26 | 4.30 | 2.45 | 1.98 | — | — | — | — | — | |
| Gross Margin | 83.58 | 81.51 | 81.77 | 82.32 | — | — | — | — | — | |
| Operating Margin | 11.04 | 8.56 | -16.75 | -26.83 | — | — | — | — | — | |
| Net Margin | -5.07 | 0.34 | -27.09 | -37.80 | — | — | — | — | — | |
| Shares Outstanding | 173 | 160 | 147 | 138 | — | — | — | — | — | |
| Market Capitalization | 1,763 | 1,256 | 498 | 324 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McCulloch Kevin | Officer | Oct 01 '26 | Sale | 9.41 | 15,000 | 141,120 | 1,599,208 | Oct 02 |
| Pieper Steven | Officer | Oct 01 '26 | Sale | 9.41 | 5,000 | 47,037 | 1,351,053 | Oct 02 |
| Hecht Beth | Officer | Oct 01 '26 | Sale | 9.41 | 16,666 | 156,792 | 1,111,130 | Oct 02 |
| McCulloch Kevin | Officer | Sep 28 '26 | Sale | 10.00 | 25,000 | 250,000 | 1,614,208 | Sep 29 |
| Pieper Steven | Officer | Sep 01 '26 | Sale | 8.50 | 5,000 | 42,500 | 1,356,053 | Sep 01 |
| Hecht Beth | Officer | Sep 01 '26 | Sale | 8.49 | 16,666 | 141,434 | 1,127,796 | Sep 01 |
| McCulloch Kevin | Officer | Sep 01 '26 | Sale | 8.49 | 15,000 | 127,308 | 1,639,208 | Sep 01 |
| Pieper Steven | Officer | Aug 12 '26 | Sale | 8.50 | 5,000 | 42,500 | 1,361,053 | Aug 12 |
| McCulloch Kevin | Officer | Aug 03 '26 | Sale | 8.02 | 15,000 | 120,240 | 1,676,126 | Aug 04 |
| Hecht Beth | Officer | Aug 03 '26 | Sale | 8.01 | 16,666 | 133,553 | 1,144,462 | Aug 04 |
| Pieper Steven | Officer | Jul 07 '26 | Sale | 8.52 | 27,600 | 235,276 | 1,366,053 | Jul 07 |
| Pieper Steven | Officer | Jul 06 '26 | Sale | 8.50 | 17,400 | 147,900 | 1,393,653 | Jul 07 |
| McCulloch Kevin | Officer | Jul 01 '26 | Sale | 8.03 | 90,000 | 722,511 | 1,691,126 | Jul 02 |
| Hecht Beth | Officer | Jul 01 '26 | Sale | 8.03 | 16,666 | 133,860 | 1,161,128 | Jul 02 |
| HALKUFF DAWN | Director | Jun 04 '26 | Sale | 6.09 | 20,000 | 121,886 | 95,000 | Jun 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.